BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34956232)

  • 21. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
    Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy.
    Liu C; Xie J; Lin B; Tian W; Wu Y; Xin S; Hong L; Li X; Liu L; Jin Y; Tang H; Deng X; Zou Y; Zheng S; Fang W; Cheng J; Dai X; Bao X; Zhao P
    Adv Sci (Weinh); 2024 Jun; 11(23):e2401061. PubMed ID: 38569519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
    Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
    BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Deleterious
    Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L
    Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
    Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy?
    Mauri D; Tsiouris S; Gkoura S; Gazouli I; Ntellas P; Amylidis A; Kampletsas L; Fotopoulos A
    Cancer Treat Res Commun; 2021; 28():100441. PubMed ID: 34404012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
    Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
    Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
    Lim JU; Yoon HK
    Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
    Xu F; He L; Zhan X; Chen J; Xu H; Huang X; Li Y; Zheng X; Lin L; Chen Y
    Aging (Albany NY); 2020 Nov; 12(24):25275-25293. PubMed ID: 33234739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers.
    Zhu Y; Yao W; Xu BC; Lei YY; Guo QK; Liu LZ; Li HJ; Xu M; Yan J; Chang DD; Feng ST; Zhu ZH
    BMC Cancer; 2021 Oct; 21(1):1167. PubMed ID: 34717582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.
    Yang J; Liu Q; Shyr Y
    Cancer Res; 2024 Feb; 84(4):626-638. PubMed ID: 38117502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TG468: a text graph convolutional network for predicting clinical response to immune checkpoint inhibitor therapy.
    Wang K; Shi J; Tong X; Qu N; Kong X; Ni S; Xing J; Li X; Zheng M
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38390990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis.
    Ding W; Chen G; Shi T
    Epigenetics; 2019 Jan; 14(1):67-80. PubMed ID: 30696380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
    Li S; Gao J; Xu Q; Zhang X; Huang M; Dai X; Huang K; Liu L
    Front Immunol; 2021; 12():693314. PubMed ID: 34177954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adrenocortical Carcinoma Steroid Profiles:
    Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
    Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors.
    Wei C; Wang M; Gao Q; Yuan S; Deng W; Bie L; Ma Y; Zhang C; Li S; Luo S; Li N
    Cancer Immunol Immunother; 2023 Jan; 72(1):23-37. PubMed ID: 35661905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.